SEC
SlamSEC
SearchBrowseEarnings

CYTOKINETICS INC

Nasdaq:CYTK
Pharmaceutical Preparations·SOUTH SAN FRANCISCO, CA
OverviewAll FilingsSum FinCreditInsidersGovernance
OverviewAll FilingsSum FinCreditInsidersGovernance

All Filings(1000 total)

TypeDateAccessionPeriodSize
4
Mar 10, 2026
0001061983-26-000018PRIMARY DOCUMENT
Mar 9, 2026
4.4 KB
4
Mar 10, 2026
0001061983-26-000017PRIMARY DOCUMENT
Mar 9, 2026
4.4 KB
4
Mar 10, 2026
0001061983-26-000016PRIMARY DOCUMENT
Mar 9, 2026
6.0 KB
4
Mar 5, 2026
0001061983-26-000015PRIMARY DOCUMENT
Mar 5, 2026
13.0 KB
144
Mar 2, 2026
0001950047-26-002009
—
4.8 KB
4
Mar 2, 2026
0001061983-26-000014PRIMARY DOCUMENT
Mar 2, 2026
4.1 KB
4
Mar 2, 2026
0001061983-26-000013PRIMARY DOCUMENT
Mar 2, 2026
8.0 KB
S-8
Feb 26, 2026
0001193125-26-077462S-8
—
190.0 KB
10-K
Feb 26, 2026
0001193125-26-07649510-K
Dec 31, 2025
16.4 MB
8-K
Feb 24, 2026
0001193125-26-0670128-K
Feb 24, 2026
431.8 KB
SCHEDULE 13G/A
Feb 17, 2026
0001897612-26-000261
—
7.3 KB
8-K
Feb 17, 2026
0001193125-26-0530498-K
Feb 17, 2026
141.0 KB
4
Feb 5, 2026
0001061983-26-000012PRIMARY DOCUMENT
Feb 5, 2026
8.2 KB
4
Feb 2, 2026
0001061983-26-000011PRIMARY DOCUMENT
Feb 2, 2026
8.0 KB
4
Jan 20, 2026
0001061983-26-000010PRIMARY DOCUMENT
Jan 15, 2026
4.4 KB
4
Jan 16, 2026
0001061983-26-000008PRIMARY DOCUMENT
Jan 15, 2026
4.3 KB
4
Jan 16, 2026
0001061983-26-000007PRIMARY DOCUMENT
Jan 15, 2026
4.4 KB
4
Jan 16, 2026
0001061983-26-000006PRIMARY DOCUMENT
Jan 15, 2026
4.4 KB
4
Jan 16, 2026
0001061983-26-000005PRIMARY DOCUMENT
Jan 15, 2026
5.1 KB
4
Jan 16, 2026
0001061983-26-000004PRIMARY DOCUMENT
Jan 15, 2026
4.4 KB
4
Jan 5, 2026
0001061983-26-000002PRIMARY DOCUMENT
Jan 5, 2026
7.7 KB
4
Jan 2, 2026
0001061983-26-000001PRIMARY DOCUMENT
Jan 2, 2026
9.1 KB
144
Jan 2, 2026
0001950047-26-000082
—
9.7 KB
4
Dec 30, 2025
0001061983-25-000057PRIMARY DOCUMENT
Dec 29, 2025
4.2 KB
144
Dec 29, 2025
0001950047-25-010741
—
8.2 KB
25 filings shown

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

CEO
Blum Robert I